Physician profile
Devon P Lappin
NPI 1194235507
$8,454.93
in general payments reported to CMS, 2019-2025
30 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,590 · 2022: $1,422 · 2023: $2,578 · 2024: $1,641 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384 · Education: $57.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,384.48 |
| Education | $57.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,013.25 | 2021-2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,272.61 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $824.65 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $578.77 | 2021-2025 | Dupixent |
| Philips North America LLC | $487.48 | 2021-2024 | (Ak6) Vest Therapy |
| Grifols USA, LLC | $428.08 | 2021-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.69 | 2021-2024 | Spiriva Respimat, Ofev |
| Insmed, INC. | $238.20 | 2021-2024 | Arikayce |
| Sanofi-Aventis U.S. LLC | $182.99 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $166.17 | 2021-2022 | |
| Optinose US, INC. | $156.38 | 2024 | |
| Cvrx, INC. | $108.27 | 2024 | Barostim Neo System |
| Neurocrine Biosciences, INC. | $102.67 | 2025 | |
| Harmony Biosciences LLC | $70.50 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $62.37 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $61.67 | 2023-2024 | Smartvest |
| Inspire Medical Systems, INC. | $57.22 | 2023 | Inspire |
| United Therapeutics Corporation | $55.70 | 2024-2025 | Tyvaso, Tyvaso |
| Genentech USA, INC. | $55.15 | 2025 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $36.06 | 2024-2025 | Lumryz |
| Verona Pharma, INC. | $35.43 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $34.62 | 2022-2023 | Airduo Digihaler |
| Amgen INC. | $33.38 | 2023 | Tezspire |
| Advanced Respiratory, INC | $23.30 | 2021 | |
| Phadia US INC. | $20.30 | 2023 | Immunocap |
| Axsome Therapeutics, INC. | $16.75 | 2025 | Sunosi |
| Mylan Specialty L.P. | $16.31 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2022 | |
| Abbvie INC. | $14.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Lappin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.